Published in J Biol Chem on January 06, 2011
TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity. Oncotarget (2014) 0.83
A balancing act: orchestrating amino-truncated and full-length p73 variants as decisive factors in cancer progression. Oncogene (2014) 0.83
Caspase-dependent Proteolysis of Human Ribonucleotide Reductase Small Subunits R2 and p53R2 during Apoptosis. J Biol Chem (2015) 0.76
Deficiency of multidrug resistance 2 contributes to cell transformation through oxidative stress. Carcinogenesis (2015) 0.75
Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem (2004) 14.93
p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature (1999) 13.21
p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell (1998) 11.54
Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res (1999) 7.82
The antioxidant function of the p53 tumor suppressor. Nat Med (2005) 7.57
Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell (1997) 7.27
Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell (1995) 7.13
p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature (2000) 5.83
p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature (1997) 5.42
TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev (2008) 4.85
p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature (2002) 4.56
Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell (2005) 4.14
Roles of nitric oxide in tumor growth. Proc Natl Acad Sci U S A (1995) 3.28
A subset of p53-deficient embryos exhibit exencephaly. Nat Genet (1995) 3.24
The changing faces of glutathione, a cellular protagonist. Biochem Pharmacol (2003) 3.16
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
The common and distinct target genes of the p53 family transcription factors. Cell Mol Life Sci (2004) 2.47
Two new p73 splice variants, gamma and delta, with different transcriptional activity. J Exp Med (1998) 2.40
The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res (2000) 2.20
TAp63 induces senescence and suppresses tumorigenesis in vivo. Nat Cell Biol (2009) 2.15
p63 and p73 in human cancer: defining the network. Oncogene (2007) 2.13
p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev (2004) 2.07
Isoform-specific p73 knockout mice reveal a novel role for delta Np73 in the DNA damage response pathway. Genes Dev (2010) 2.06
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
DeltaTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. J Clin Oncol (2005) 1.88
The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat Res (1999) 1.82
TP53 family members and human cancers. Hum Mutat (2003) 1.70
Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53. Proc Natl Acad Sci U S A (1996) 1.68
p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ (2010) 1.47
Tumor protein 53-induced nuclear protein 1 is a major mediator of p53 antioxidant function. Cancer Res (2009) 1.46
p53 expression in nitric oxide-induced apoptosis. FEBS Lett (1994) 1.42
One, two, three--p53, p63, p73 and chemosensitivity. Drug Resist Updat (2007) 1.41
Promoter specificity and stability control of the p53-related protein p73. Oncogene (1999) 1.36
Therapeutic prospects for p73 and p63: rising from the shadow of p53. Drug Resist Updat (2008) 1.32
Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett (1998) 1.32
Identification of direct p73 target genes combining DNA microarray and chromatin immunoprecipitation analyses. J Biol Chem (2002) 1.29
Glutathione levels and sensitivity to apoptosis are regulated by changes in transaldolase expression. J Biol Chem (1996) 1.28
p38 kinase regulates nitric oxide-induced apoptosis of articular chondrocytes by accumulating p53 via NFkappa B-dependent transcription and stabilization by serine 15 phosphorylation. J Biol Chem (2002) 1.21
Up-regulation of inducible nitric oxide synthase expression in cancer-prone p53 knockout mice. Proc Natl Acad Sci U S A (1998) 1.12
Nitric oxide and superoxide: interference with hypoxic signaling. Cardiovasc Res (2007) 1.12
Activation of the cell death program by nitric oxide involves inhibition of the proteasome. J Biol Chem (1999) 1.12
Radiosensitization by Chir-124, a selective CHK1 inhibitor: effects of p53 and cell cycle checkpoints. Cell Cycle (2009) 1.11
Glutathione levels and BAX activation during apoptosis due to oxidative stress in cells expressing wild-type and mutant cystic fibrosis transmembrane conductance regulator. J Biol Chem (2002) 1.10
Nitric oxide-induced genotoxicity, mitochondrial damage, and apoptosis in human lymphoblastoid cells expressing wild-type and mutant p53. Proc Natl Acad Sci U S A (2002) 1.06
p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes. Cancer Res (2009) 1.05
Deletion of the COOH-terminal region of p73alpha enhances both its transactivation function and DNA-binding activity but inhibits induction of apoptosis in mammalian cells. Cancer Res (1999) 1.04
p53 Activation by nitric oxide involves down-regulation of Mdm2. J Biol Chem (2002) 1.02
Viral mutation accelerated by nitric oxide production during infection in vivo. FASEB J (2000) 1.02
p73 supports cellular growth through c-Jun-dependent AP-1 transactivation. Nat Cell Biol (2007) 1.01
Inhibition of S-phase progression triggered by UVA-induced ROS does not require a functional DNA damage checkpoint response in mammalian cells. DNA Repair (Amst) (2008) 0.98
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther (2005) 0.97
p73beta-Mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Res (2005) 0.96
Full-length p73alpha represses drug-induced apoptosis in small cell lung carcinoma cells. J Biol Chem (2005) 0.95
Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73. J Biol Chem (2003) 0.93
Influence of nitric oxide on the intracellular reduced glutathione pool: different cellular capacities and strategies to encounter nitric oxide-mediated stress. Free Radic Biol Med (1999) 0.86
Depletion of deoxyribonucleoside triphosphate pools in tumor cells by nitric oxide. Free Radic Biol Med (2004) 0.84
Upregulation of the p53R2 ribonucleotide reductase subunit by nitric oxide. Nitric Oxide (2008) 0.83
Protection by glutathione against the antiproliferative effects of nitric oxide. Dependence on kinetics of no release. Biochem Pharmacol (1996) 0.78
p-Alkoxyphenols, a new class of inhibitors of mammalian R2 ribonucleotide reductase: possible candidates for antimelanotic drugs. Mol Pharmacol (1994) 0.76
Murine Nod1 but not its human orthologue mediates innate immune detection of tracheal cytotoxin. EMBO Rep (2005) 1.41
Increased expression of the large subunit of ribonucleotide reductase is involved in resistance to gemcitabine in human mammary adenocarcinoma cells. Mol Cancer Ther (2005) 0.97
Anti-tumoral effect of a celecoxib low dose on a model of human medullary thyroid cancer in nude mice. Thyroid (2009) 0.88
Depletion of deoxyribonucleoside triphosphate pools in tumor cells by nitric oxide. Free Radic Biol Med (2004) 0.84
Inhibitors of CTP biosynthesis potentiate the anti-human immunodeficiency virus type 1 activity of 3TC in activated peripheral blood mononuclear cells. Antiviral Res (2004) 0.83
Upregulation of the p53R2 ribonucleotide reductase subunit by nitric oxide. Nitric Oxide (2008) 0.83
Cellular antiendotoxin activities of lung surfactant protein C in lipid vesicles. Am J Respir Crit Care Med (2003) 0.83
Direct preparation of nucleoside vinyl disulfides from 2-(trimethylsilyl)ethyl sulfides, an access to vinylthiols. Org Lett (2007) 0.80
Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: particular potency of 1H-indazole-7-carbonitrile. Bioorg Med Chem (2008) 0.77
First non-alpha-amino acid guanidines acting as efficient NO precursors upon oxidation by NO-synthase II or activated mouse macrophages. Biochemistry (2002) 0.76
Synthesis and evaluation of pyrido[1,2-a]pyrimidines as inhibitors of nitric oxide synthases. Eur J Med Chem (2008) 0.75
Deoxyribonucleoside 2'- or 3'-mixed disulfides: prodrugs to target ribonucleotide reductase and/or to inhibit HIV reverse transcription. J Med Chem (2003) 0.75
Glutathione depletion reveals impairment of antigen processing and inhibition of cathepsin activity by nitric oxide in antigen-presenting cells. Mol Immunol (2008) 0.75